---
title: "SIM0725 is a long-acting antagonistic monoclonal antibody targeting the interleukin-2 receptor beta… — 先聲藥業集團 — DecisionGateway"
description: "statement by 先聲藥業集團, recorded recently — verbatim quote and source citation."
canonical_url: "https://dgw.tmarket.io/claims/01a1d903-deed-7a5c-ba12-ed328cc73381"
meta:
  "og:description": "statement by 先聲藥業集團, recorded recently — verbatim quote and source citation."
  "og:image": "https://dgw.tmarket.io/og.jpg"
  "og:image:alt": "White network of connected nodes crossed by a timeline on black"
  "og:image:height": "1024"
  "og:image:width": "1024"
  "og:title": "SIM0725 is a long-acting antagonistic monoclonal antibody targeting the interleukin-2 receptor beta… — 先聲藥業集團 — DecisionGateway"
  "twitter:image": "https://dgw.tmarket.io/og.jpg"
---

> Index of every page on this site: [llms.txt](https://dgw.tmarket.io/llms.txt)

statement

# **SIM0725 is a long-acting antagonistic monoclonal antibody targeting the interleukin-2 receptor beta chain (CD122).**

A statement by [**先聲藥業集團**](https://dgw.tmarket.io/actors/01a1d903-deb0-7451-9aea-911c778a672b). Statements are as reported by the cited publishers — not verified by DecisionGateway.

> *靶向白細胞介素-2受體β鏈（CD122）長效拮抗型單克隆抗體SIM0725*

stockintelligencenewsPublished 2026-11-10 [ Read source](https://t.me/stockintelligencenews/5713659)

[**先聲藥業集團 dossier **](https://dgw.tmarket.io/actors/01a1d903-deb0-7451-9aea-911c778a672b)

## **Discussion**

## **Related claims**

[**SIM0725 has been approved by the National Medical Products Administration to conduct clinical trials in China.**先聲藥業集團 · investigation](https://dgw.tmarket.io/claims/01a1d903-dedc-7f65-a559-750a8781566d) [**SIM0725 is intended for the treatment of autoimmune diseases.**先聲藥業集團 · statement](https://dgw.tmarket.io/claims/01a1d903-dee5-7dfa-b463-3177957abb5f) [**SIM0725 was independently developed by the company.**先聲藥業集團 · statement](https://dgw.tmarket.io/claims/01a1d903-def4-7b63-8f8d-33fa088582cc) [**IMVT-1402 is designed so its binding epitope does not compete with albumin, allowing high-dose continuous administration without hypercholesterolemia concerns, whereas Batoclimab requires dose reduction after several weeks.**하나증권 제약/바이오 김선아 · statement](https://dgw.tmarket.io/claims/01a1d887-39ba-7ec3-9b03-4f53807d90d5) [**CagriSema consists of the long-acting amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide.**界面新闻 · statement](https://dgw.tmarket.io/claims/01a1d24c-485a-7af6-9fa1-7aa87fd66188) [**IMVT-1402 in refractory rheumatoid arthritis achieved statistical significance in the Period 2 ACR20 response rate, with the 600mg group meeting key endpoints at week 28 on both ACR20 and ACR50 versus placebo.**현대차증권 제약/바이오/의료기기 김현석 · statement](https://dgw.tmarket.io/claims/01a1d950-db09-704e-b002-22ff5c6d58f3)

## **More claims by 先聲藥業集團**

[**SIM0725 was independently developed by the company.**statement](https://dgw.tmarket.io/claims/01a1d903-def4-7b63-8f8d-33fa088582cc) [**SIM0725 is intended for the treatment of autoimmune diseases.**statement](https://dgw.tmarket.io/claims/01a1d903-dee5-7dfa-b463-3177957abb5f) [**SIM0725 has been approved by the National Medical Products Administration to conduct clinical trials in China.**investigation](https://dgw.tmarket.io/claims/01a1d903-dedc-7f65-a559-750a8781566d)

[All claims by 先聲藥業集團](https://dgw.tmarket.io/claims?claimant_id=01a1d903-deb0-7451-9aea-911c778a672b)

[All claims](https://dgw.tmarket.io/claims)

```json
{"@context":"https://schema.org","@graph":[{"@id":"https://dgw.tmarket.io/#website","@type":"WebSite","description":"Decisions, events and falsifiable forecasts from 4,000+ Telegram channels — every claim cited. Read free.","name":"DecisionGateway","url":"https://dgw.tmarket.io/","publisher":{"@id":"https://dgw.tmarket.io/#identity"}},{"@id":"https://dgw.tmarket.io/claims/01a1d903-deed-7a5c-ba12-ed328cc73381#webpage","@type":"WebPage","description":"statement by 先聲藥業集團, recorded recently — verbatim quote and source citation.","name":"SIM0725 is a long-acting antagonistic monoclonal antibody targeting the interleukin-2 receptor beta… — 先聲藥業集團 — DecisionGateway","url":"https://dgw.tmarket.io/claims/01a1d903-deed-7a5c-ba12-ed328cc73381","breadcrumb":{"@id":"https://dgw.tmarket.io/claims/01a1d903-deed-7a5c-ba12-ed328cc73381#breadcrumb"},"isPartOf":{"@id":"https://dgw.tmarket.io/#website"},"potentialAction":[{"@type":"ReadAction","target":["https://dgw.tmarket.io/claims/01a1d903-deed-7a5c-ba12-ed328cc73381"]}]},{"@id":"https://dgw.tmarket.io/#identity","@type":"Organization","name":"DecisionGateway","url":"https://dgw.tmarket.io"},{"@id":"https://dgw.tmarket.io/claims/01a1d903-deed-7a5c-ba12-ed328cc73381#breadcrumb","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","name":"Home","item":"https://dgw.tmarket.io","position":1},{"@type":"ListItem","name":"Claims","item":"https://dgw.tmarket.io/claims","position":2},{"@type":"ListItem","name":"SIM0725 is a long-acting antagonistic monoclonal antibody…","position":3}]},{"@id":"https://dgw.tmarket.io/claims/01a1d903-deed-7a5c-ba12-ed328cc73381#/schema/quotation/1","@type":"Quotation","dateCreated":"2026-11-10","isBasedOn":"https://t.me/stockintelligencenews/5713659","text":"靶向白細胞介素-2受體β鏈（CD122）長效拮抗型單克隆抗體SIM0725","url":"/claims/01a1d903-deed-7a5c-ba12-ed328cc73381","spokenByCharacter":{"@type":"Person","name":"先聲藥業集團","@id":"/actors/01a1d903-deb0-7451-9aea-911c778a672b"}}]}
```

## Sitemap

See the full [sitemap](https://dgw.tmarket.io/sitemap.md) for all pages.